JAMDA
Volume 6, Issue 4 , Pages 238-245 , July 2005

The Use of the Occupational Disruptiveness Scale of the Neuropsychiatric Inventory-Nursing Home Version to Measure the Impact of Rivastigmine on the Disruptive Behavior of Nursing Home Residents With Alzheimer’s Disease

  • Hind T. Hatoum, PhD

      Affiliations

    • Hind T. Hatoum & Company, Chicago, IL
    • University of Illinois, Chicago, IL
    • Corresponding Author InformationAddress correspondence to Hind T. Hatoum, PhD, Hind T. Hatoum & Company, 1758 N. Wilmot Ave., Chicago, IL 60647.
    • ,
  • Swu-Jane Lin, PhD

      Affiliations

    • University of Illinois, Chicago, IL
    • ,
  • Stephen Arcona, PhD

      Affiliations

    • Novartis Pharmaceutical Corporation, East Hanover, NJ
    • ,
  • Simu K. Thomas

      Affiliations

    • Novartis Pharmaceutical Corporation, East Hanover, NJ
    • ,
  • Barbara Koumaras, BA

      Affiliations

    • Novartis Pharmaceutical Corporation, East Hanover, NJ
    • ,
  • Dario Mirski, MD

      Affiliations

    • Novartis Pharmaceutical Corporation, East Hanover, NJ

References 

  1. Alzheimer’s Foundation of America. Available at: www.afa-vantage.com. Accessed March 31, 2004.
  2. Hebert LE , Scherr PA , Bienias JL , et al.   Alzheimer disease in the US population (Prevalence estimates using the 2000 census) . Arch Neurol . 2003;60:1119–1122
  3. Evans DA , Funkenstein HH , Albert MS , et al.   Prevalence of Alzheimer’s disease in a community population of older persons (Higher than previously reported) . JAMA . 1989;262:2552–2556
  4. In: National Nursing Home Survey . Hyattsville, MD: National Center for Health Statistics; 1985;p. 49
  5. Ernst RL , Hay JW . The US economic and social costs of Alzheimer’s disease revisited . Am J Public Health . 1994;84:1261–1264
  6. Koppel R . Alzheimer’s Disease (The Costs to US Businesses in 2002) . Washington, DC: Alzheimer’s Association; 2002;
  7. Fox PJ , Kohatsu N , Max W , Arnsberger P . Estimating the costs of caring for people with Alzheimer disease in California (2000–2040) . J Public Health Policy . 2001;22:88–97
  8. Souetre EJ , Qing W , Vigoureux I , et al.   Economic analysis of Alzheimer’s disease in outpatients (Impact of symptom severity) . Int Psychogeriatr . 1995;7:115–122
  9. Leon J , Neumann PJ . The cost of Alzheimer’s disease in managed care (a cross-sectional study) . Am J Manag Care . 1999;5:867–877
  10. Brookmeyer R , Gray S , Kawas C . Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset . Am J Public Health . 1998;88:1337–1342
  11. Cummings JL , McPherson S . Neuropsychiatric assessment of Alzheimer’s disease and related dementias . Aging (Milano) . 2001;13:240–246
  12. Murman DL , Chen Q , Powell MC , et al.   The incremental direct costs associated with behavioral symptoms in AD . Neurology . 2002;59:1721–1729
  13. O’Donnell BF , Drachman DA , Barnes HJ , et al.   Incontinence and troublesome behaviors predict institutionalization in dementia . J Geriatr Psychiatry Neurol . 1992;5:45–52
  14. Yaffe K , Fox P , Newcomer R , et al.   Patient and caregiver characteristics and nursing home placement in patients with dementia . JAMA . 2002;287:2090–2097
  15. Moore MJ , Zhu CW , Clipp EC . Informal costs of dementia care (Estimates from the National Longitudinal Caregiver Study) . J Gerontol B Psychol Sci Soc Sci . 2001;56:S219–S228
  16. Fillit H , Hill JW , Futterman R . Health care utilization and costs of Alzheimer’s disease (The role of co-morbid conditions, disease stage, and pharmacotherapy) . Fam Med . 2002;34:528–535
  17. Martin BC , Ricci JF , Kotzan JA , et al.   The net cost of Alzheimer disease and related dementia (A population-based study of Georgia Medicaid recipients) . Alzheimer Dis Assoc Disord . 2000;14: 151–19
  18. Rice DP , Fillit HM , Max W , et al.   Prevalence, costs, and treatment of Alzheimer’s disease and related dementia (A managed care perspective) . Am J Manag Care . 2001;7:809–818
  19. Enz A , Amstutz R , Boddeke H , et al.   Brain selective inhibition of acetylcholinesterase (A novel approach to therapy for Alzheimer’s disease) . Prog Brain Res . 1993;98:431–438
  20. Corey-Bloom J , Anand R , Veach J  ENA 713 B352 Study Group . A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease . Intl J Geriatr Psychopharmacol . 1998;1:55–65
  21. Rosler M , Anand R , Cicin-Sain A , et al.   Efficacy and safety of rivastigmine in patients with Alzheimer’s disease (International randomised controlled trial) . BMJ . 1999;318:633–638
  22. Aupperle PM , Koumaras B , Chen M , Rabinowicz A , Mirski D . Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease (Results of a 52-week open-label study) . Curr Med Res Opin . 2004;20:1605–1612
  23. McKhann G , Drachman D , Folstein M , et al.   Clinical diagnosis of Alzheimer’s disease (Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease) . Neurology . 1984;34:939–944
  24. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders . 4th ed (revised). Washington, DC: American Psychiatric Association; 1994;
  25. Folstein MF , Folstein SE , McHugh PR . “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician . J Psychiatr Res . 1975;12:189–198
  26. Wood S , Cummings JL , Hsu MA , et al.   The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement . Am J Geriatr Psychiatry . 2000;8:75–83
  27. Rosen WG , Mohs RC , Davis KL . A new rating scale for Alzheimer’s disease . Am J Psychiatry . 1984;141:1356–1364
  28. Kaufer DI , Cummings JL , Christine D , et al.   Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease (The Neuropsychiatric Inventory Caregiver Distress Scale) . J Am Geriatr Soc . 1998;46:210–215
  29. The Lewin Group. Medicare and Medicaid Costs for People with Alzheimer’s Disease. [An unpublished report funded by the Alzheimer Association, Washington, DC, April 2001; p. 1.] Available at: http://www.alz.org/AboutAD/Statistics.asp. Accessed May 30, 2004.
  30. Gabelli C . Rivastigmine (An update on therapeutic efficacy in Alzheimer’s disease and other conditions) . Curr Med Res Opin . 2003;19:69–82
  31. Schumock GT . Economic considerations in the treatment and management of Alzheimer’s disease . Am J Health Syst Pharm . 1998;55(Suppl 2):S17–S21
  32. Fillit HM . The pharmacoeconomics of Alzheimer’s disease . Am J Manag Care . 2000;6(22 Suppl):S1139–S1144 discussion S1145–8
  33. Wu G , Lanctot KL , Herrmann N , et al.   The cost-benefit of cholinesterase inhibitors in mild to moderate dementia (A willingness-to-pay approach) . CNS Drugs . 2003;17:1045–1057
  34. Getsios D , Caro JJ , Caro G , et al.   Assessment of health economics in Alzheimer’s disease (AHEAD) (Galantamine treatment in Canada) . Neurology . 2001;57:972–978
  35. Bell CM , Araki SS , Neumann PJ . The association between caregiver burden and caregiver health-related quality of life in Alzheimer disease . Alzheimer Dis Assoc Disord . 2001;15:129–136
  36. Jonsson L . Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer’s disease . Pharmacoeconomics . 2003;21:1025–1037
  37. Lovestone S , Graham N , Howard R . Guidelines on drug treatments for Alzheimer’s disease . Lancet . 1997;350:232–233

PII: S1525-8610(05)00244-6

doi: 10.1016/j.jamda.2005.04.003

JAMDA
Volume 6, Issue 4 , Pages 238-245 , July 2005

Article Tools